{"name":"Boundless Bio, Inc.","slug":"boundless-bio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BBI-355","genericName":"BBI-355","slug":"bbi-355","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"BBI-355","genericName":"BBI-355","slug":"bbi-355","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNd0JZSkFPMTdNLTF4RzU4V0xLTWxWM1E0SzdZX2JYejhfVWJDS0s1STBTQVRacnlxdl8wZTJPR181YzkwazlVRENDWElIcGhIdkJSSUFnUndsOTNLT3lSbzZSRHlDWUZTNEhKTXRvc3dSYmlkcVJNTGpOM01yaTFzRjY0Z3BwT3lsYkd5aW93T3g2bTJEZHo3ZHJjR1U3cUxMcVFScmZ3WTdHdWVYR3FMS0FzTmgzQ1R2M3JFSTVzWlZDMTE3ZUU0UngyMjhDZDFoeXhmdWZiZVZIM0NGZ0RWQmVGSGw1Uk5WYVVCTmdNRnhHcG1pVFE?oc=5","date":"2026-03-27","type":"pipeline","source":"Barchart.com","summary":"Checkpoint Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, ROA, Molecules, Companies and Future Outlook - Barchart.com","headline":"Checkpoint Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, ROA, Molecules, Companies and Future Ou","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOM2pseTNmajViNVVpT21mSFBYSFN3MlFnNGh2UFhacVVzTTh1ZS1hTWNBSWNuX0pYVTdheGthVEtzSGlhTG9UVDV3TllTN2Z2WGI0ZlgyZFNsSGtzSW8wM0VFTl9PUWtFQ09zaU5jLXlwbkJVQWNUaXVZeUZXTVF4NnhDektVTzlCakxyZzBiWE1VSFYxcGpsS2dIMm4yVks5T1pVU2ItV3VYdG16U2E5Y2JlN0dSMHJ1cksxQ2o5cmlUZ2lUV1d3SG1vMWJFdXM?oc=5","date":"2026-03-20","type":"pipeline","source":"seekingalpha.com","summary":"Boundless Bio: Underestimated Biotech With First-In-Class EcDNA Targeted Kinesin Degrader - seekingalpha.com","headline":"Boundless Bio: Underestimated Biotech With First-In-Class EcDNA Targeted Kinesin Degrader","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNZ0RLWXpENGVzZ2ZMWTJ5MTkyN3BRUzRuV3BiOTVqS0VnRTJxeXVJSzlVZjJnS1BuS19tMnE0dW5taHRSSEtSRG1wYkJZOTAyUzNmWm5XNy1lNkF1RFEtS2RPbTdTTmVpOTJXZ0xQVkJBTDYzLWpDTEN4cU9WVUU3VTBmSVYzbGxKcXZreTJpYWFIUzM3V3BJOTJ5Q0lGMXZhUllKYWlydEd5aE5hdm9sNGpCbXJSTXM?oc=5","date":"2026-03-17","type":"pipeline","source":"Stock Titan","summary":"Inside a novel cancer drug aiming at ecDNA-positive, high-risk breast tumors - Stock Titan","headline":"Inside a novel cancer drug aiming at ecDNA-positive, high-risk breast tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOakltZ002cjV6V0M2d0lNQVZWRndOUlZ5d0huRjVDRGkyUzFuZVhYYjd0QUlucU5YRGVqUlg1S3dQNnlBeDFMS0dfNHRLMElLR3ktd1E1Y2VmclpQWFJjXy1jYzhwQmpRbTdIbkp2NE9JZmV4X1FIalk2VGhORFQ4NXNNMnpYeHBVN3VxMGc4eVJzU1FGUk53cmxhcjJXMVZ2OXZPaTN2QjdsQQ?oc=5","date":"2026-03-09","type":"pipeline","source":"Stock Titan","summary":"Boundless Bio (Nasdaq: BOLD) trims 2025 loss, funds KOMODO-1 into 2028 - Stock Titan","headline":"Boundless Bio (Nasdaq: BOLD) trims 2025 loss, funds KOMODO-1 into 2028","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-04","type":"pipeline","source":"simplywall.st","summary":"Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth? - simplywall.st","headline":"Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQU3RaWnNGSGpzUmJmZkxiZm5PTlRJdTc2YXpZczNKSTJfOU02aDJlSGlhYVlfRjdINURYSVhaM0RDOUFkaktKdzF3dXhWWWlOaGZicjQ1NFZKcGVlVFZVWERQdkYxdjJsWGo1eE04QmxxdXFyRmNNNlNxS1lNdnpIRUhuQ1VsUG5rNHBIZXBLZzZzaGVpclE?oc=5","date":"2026-01-21","type":"regulatory","source":"BioWorld News","summary":"Boundless Bio’s kinesin degrader gains IND approval - BioWorld News","headline":"Boundless Bio’s kinesin degrader gains IND approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQbGpoNGVkN0JtYVpQa2w0Y1JyZ1k1ZF9ET3Jwcm1HVVFpM2JrUEM1LXJYU3JwY3VJTVN1TGRGWHRMdmpTbFFFSTlZYjZoS3pjTmtibVNrc2RBZ2R4ZWJrM3pNN0VYVC1iQ2wwcVZra2s5MGZiVFJzOHJQWE9nNmdIdm1SeW91bGJLMGV0TzRkblVvNG83MGFlMzE5Q0tXNTFQc0tVQmxBa3c0anJTZFpxNzhYcUpjVW1OX2Z5VQ?oc=5","date":"2026-01-20","type":"trial","source":"Stock Titan","summary":"Boundless Bio halts trial to back new breast cancer drug to 2028 - Stock Titan","headline":"Boundless Bio halts trial to back new breast cancer drug to 2028","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOOGlLWWVKcEpnS3dUaGw5bWRSM2x5NFhoZ2M5cXRQWThpSjczT3JoODVkNTNkdWYtd3RybmgtU1B4RmdONjhnbEJsVFhwcFZ2QXZYSEFvMkZ3VmdUYWQ3VTh4R29GU0ZPUWJnaU5qQ0xMeTJ0TXZNREQwZTI0WUtIRVMwaklUT0w0U3VHTnlTTmw?oc=5","date":"2025-05-27","type":"pipeline","source":"Fierce Biotech","summary":"Boundless Bio lays off 33% of staff as lead program stumbles - Fierce Biotech","headline":"Boundless Bio lays off 33% of staff as lead program stumbles","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPS3lUaEJpQlBrejhfdENkd0x2WUFWSnVYOWhqMHRPYXVGMHZ6MEpITFJYSi0zdHdzWk9VT1phQnBYSTZFOEtFVk10cjN4NXJzYU9HNWVpaVFMT2Rjejg0OGN0SG9IRGJ2QXdUb3NRMzd1c19ycHhUZTc2WURkYkFGdDh1dw?oc=5","date":"2025-05-10","type":"pipeline","source":"The Pharma Letter","summary":"Boundless Bio reports R&D pipeline progress - The Pharma Letter","headline":"Boundless Bio reports R&D pipeline progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxObklWM3d5S1BHa0xyWEZ6ckFOZENXUHVRYnByS0RvX0FBZjZPdWRGX0pNbXBxTkgyeGxFZVFlX1Q1X3JRVDlYM3B0UFE3TDh2b0ZHbGptYU9TYVZHclVXeXN1LV9kdC0xRTNqQUVTdDhDQ0lRWC05UkpOaHdtYVQxRlBGaE15bVhMWm9wNzFuVTZXNDVSNk04NjV3SnZGXzI0?oc=5","date":"2024-12-13","type":"trial","source":"Fierce Biotech","summary":"Boundless Bio drops clinical-stage cancer drug over phase 1 data, shakes up C-suite - Fierce Biotech","headline":"Boundless Bio drops clinical-stage cancer drug over phase 1 data, shakes up C-suite","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxPazlENzlSRzRoT0VXOUlIb0pQNDBmbktTTEVTQmtGM0h3cUpQVXY3WENTa1c2MVAydmEzMWVpMU9BTWJQalNUYXB2UkRfbnJLTmF1OV9Lbkw1czhsWG5nUzVFaV9kemlpTzRmbUxEUGJvOU0wNl95ODdGVk1DMEg1VDRPY3hIRlRydE5ua2RjOG9SeXZNQmwtMUc5MExIckw1WDJYd251di1zSWtMenFtYTlrakl1aVJWelhjQUZpM0tMdUVqQjFpbTFwSnhITUtuRTFvS0RlVnUweXNSZUNsLXlYaDRhZUJkYnpiYkxTelNpM0djWWZTcUQxMXp3cFN4SVJWVGg4OXlIbk55RU9xYThNY0o2LWo2X2xNcWlpYW5BU2FM?oc=5","date":"2024-09-05","type":"trial","source":"PR Newswire","summary":"SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024 - PR Newswire","headline":"SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinica","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQNVUzSjNHWXpObldmYkowUWFEcXgtVjd3aDc2U0xtTVo0NkhiT01hVWtRWHdwR0VMYktKNzRROTFvVVphMU9yMlhBTll1NEtsMFN5WldGV0Uyb0RLd0RSbEdVcTE0QW9uZ1RMa2JWM1B0M1FVWTFuTUZRUlVySDNKRHJHS2hrQmRoTVRRNg?oc=5","date":"2024-03-07","type":"pipeline","source":"BioPharma Dive","summary":"Boundless Bio, a Bayer-backed cancer biotech, seeks an IPO - BioPharma Dive","headline":"Boundless Bio, a Bayer-backed cancer biotech, seeks an IPO","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}